How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Hirsutism (Treatment)

hirsutism. Sibutramine (withdrawn from US market October 8, 2010 [ ] ): Weight loss with this anorectic agent improves hirsutism scores, androgen levels, and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). Cosmetic measures for hirsutism and their disadvantages are as follows: Hydrogen peroxide bleaching is not suitable for severe hirsutism. Plucking can cause skin irritation, folliculitis, and scarring. Waxing can cause skin irritation, folliculitis, and scarring. The wax

2014 eMedicine.com

202. Obesity (Treatment)

Activity Oude et al concluded that, although no one treatment program can be conclusively recommended, combined behavioral lifestyle interventions produce a significant reduction in weight. Although orlistat and sibutramine (withdrawn from US market) may be used as adjuncts to lifestyle interventions, they must be carefully considered. [ ] Smoking tobacco reduces appetite and is used by many adults and some teenagers to prevent or limit weight gain. The deleterious consequences of smoking clearly (...) . . Coffield JE, Metos JM, Utz RL, Waitzman NJ. A multivariate analysis of federally mandated school wellness policies on adolescent obesity. J Adolesc Health . 2011 Oct. 49(4):363-70. . Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev . 2011 Dec 7. 12:CD001871. . Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled

2014 eMedicine Pediatrics

203. Catatonia (Diagnosis)

malignant syndrome [ ] Administration of agents that block postsynaptic dopamine receptors* Administration of sibutramine [ ] (withdrawn from US market October 8, 2010) Withdrawal of lorazepam and other sedatives Akinetic-rigid syndrome Anti-NMDA receptor encephalitis [ ] Arachnoid cyst in right parietal region Astrocytoma Atrophy of left amygdala [ ] Autistic disorder [ , , , , , , , , , , ] Basilar artery thrombosis Bilateral hemorrhagic lesions of temporal lobes Cerebellar catalepsy Cerebral (...) and neuroleptic malignant syndrome related conditions?]. L’Encéphale . 2009. Lee J, Teoh T, Lee TS. Catatonia and psychosis associated with sibutramine: a case report and pathophysiologic correlation. J Psychosom Res . 2008 Jan. 64(1):107-9. . Neto B. Catatonia with left temporal lesion on MRI: crossing borders. European Psychiatry . 2009. 24 supplement 1:S727. Wachtel L. Catatonia in autism: Etiology, incidence and treatment [abstract]. European Psychiatry . 2008. 23:S402-S402. Wachtel LE, Contrucci-Kuhn SA

2014 eMedicine.com

204. Obesity (Overview)

, Waitzman NJ. A multivariate analysis of federally mandated school wellness policies on adolescent obesity. J Adolesc Health . 2011 Oct. 49(4):363-70. . Waters E, de Silva-Sanigorski A, Hall BJ, et al. Interventions for preventing obesity in children. Cochrane Database Syst Rev . 2011 Dec 7. 12:CD001871. . Daniels SR, Long B, Crow S, et al. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study. Pediatrics . 2007 Jul (...) . 120(1):e147-57. . Berkowitz R, Fujioka K, Daniels S, et al. Effects of sibutramine treatment in obese adolescents. A randomized trial. Ann Intern Med . July 2006. 145:81-90. . Abbott Laboratories agrees to withdraw its obesity drug Meridia. FDA, U.S. Food and Drug Administration. Available at . Accessed: October 8, 2010. Dunican KC, Desilets AR, Montalbano JK. Pharmacotherapeutic options for overweight adolescents. Ann Pharmacother . 2007 Sep. 41(9):1445-55. . Bray GA, Ryan DH. Drug treatment

2014 eMedicine Pediatrics

205. Unstable Angina (Diagnosis)

. Safety: Meridia (sibutramine): market withdrawal due to risk of serious cardiovascular events. US Food and Drug Administration. October 8, 2010. Available at . Accessed: June 5, 2013. Soukoulis V, Boden WE, Smith SC Jr, O'Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res . 2014 Jun 6. 114(12):1944-58. . . Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical

2014 eMedicine.com

206. Polycystic Ovarian Syndrome (Diagnosis)

injury. Posted: March 1, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: statin drugs - drug safety communication: class labeling change. Posted: February 28, 2012. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Zocor (simvastatin): label change - new restrictions, contraindications, and dose limitations. Posted: June 8, 2011. Available at . Accessed: May 22, 2012. US Food and Drug Administration. Safety: Meridia (sibutramine

2014 eMedicine.com

208. Stimulants (Diagnosis)

) Phentermine - Fastin, Ionamin, Adipex Pipradrol Sibutramine - Meridia (withdrawn from US market October 8, 2010) Schedule V These substances have an abuse potential less than those in schedule IV. Schedule V controlled substances consist of preparations containing limited quantities of certain narcotic drugs and are generally for antitussive and antidiarrheal purposes. These drugs are subject to state and local regulation, and a prescription may not be required. Schedule V stimulants include pyrovalerone (...) to stop sales and marketing of pemoline. Sibutramine (Meridia) is a combination serotonin and norepinephrine and dopamine reuptake inhibitor whose appetite-suppressive effects appear to be related to its noradrenergic action. When its noradrenergic activity is blocked, the appetite suppression is lost. Selective serotonin reuptake inhibitors cause initial transient anorexia without causing long-term weight loss. Sibutramine is no longer marketed. On October 8, 2010, Abbott and the US Food and Drug

2014 eMedicine.com

210. The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Trial

) and to have maintained a stable body weight for the previous 3 months. Exclusion Criteria: any co-morbid conditions that would make participation in a walking program medically inadvisable. subjects currently participating in a diet or lifestyle intervention for weight loss or who are on medications known to influence bodyweight or glucoregulation (including antidepressants, sibutramine orlistate, insulin and metformin), will be excluded. If participants are scheduled for any type of surgery that could

2013 Clinical Trials

211. Efficacy and Safety of Alogliptin and Metformin Fixed-dose Combination in Patients With Type 2 Diabetes

inhibitor and/or metformin or related compounds. Has used oral or systemically injected glucocorticoids (including intra-articular injection) or has used weight-loss drugs within 2 months prior to Screening. (Inhaled or topical corticosteroids were allowed.) History of alcohol or substance abuse within 2 years prior to Screening. Has used medicine for weight loss within 60 days prior to Screening (such as Xenical, Sibutramine, Phenylpropanolamine or similar nonprescription drugs). History of organ

2013 Clinical Trials

212. Targeting Inflammation to Treat Cardiovascular Aging

.) are not included in this study because we are studying healthy middle-aged/older adults. Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study. Hemoglobin <12 mg/dl for men; < 10 mg/dl for women History of alcohol abuse or >10 alcoholic units per week (1 unit= 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 oz alcohol) Low platelets (<100,000 cu mm) On weight loss drugs (e.g., Xenical (orlistat), Meridia (sibutramine

2013 Clinical Trials

213. Exercise Resistance in Type 2 Diabetes

, cardiac, liver, lung, or neurological disease that in the opinion of the Investigator would compromise participant safety (A) Use of drugs known to affect energy metabolism or body weight: including, but not limited to: orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc (A) Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures. (A) New onset (<3 months on a stable regime) hormone replacement therapy. (A) Alcohol

2013 Clinical Trials

214. Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)

, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures New onset (<3 months on a stable regime) use of oral contraceptives or hormone replacement therapy Alcohol or other drug abuse Smoking within the past 3 months Females that are currently or have been pregnant or are currently or have nursed a child within the last 12 months (minimum). Parental enrollment into the study

2013 Clinical Trials

215. the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes

disease , GI disease, Hepatobilliary diseases, hematological disorders, hypo- or hyperthyroidism, treatment with orlistat or sibutramine for weight loss, pregnancy and lactation, treatment with insulin or Thiazolidinediones, Smokers Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2013 Clinical Trials

216. Antiobesity Effect of Codonopsis lanceolata in High-Calorie/High-Fat-Diet-Induced Obese Rats. Full Text available with Trip Pro

, p.o.), HFD, HFD + wCL (100, 300, or 900 mg/kg/day, p.o.), HFD + cCL (100, 300, or 900 mg/kg/day, p.o.), and HFD + sibutramine. The body weight gains of the administered HFD + CL (wCL or CCL) were lower than those of the rats fed with only the HFD group. Moreover, the weight of adipose pads and the serum levels of triglycerides, total cholesterol, and low density lipoprotein cholesterol in the group administered HDL + CL were significantly lower than in the HFD group. The inhibitory effect of lipid

2013 Evidence-based Complementary and Alternative Medicine (eCAM)

217. Inflammation Inhibition in Prediabetic Humans

are studying healthy middle-aged/older adults. Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study. Hemoglobin <12 mg/dl for men; < 10 mg/dl for women History of alcohol abuse or >10 alcoholic units per week (1 unit= 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 oz alcohol) Low platelets (<100,000 cu mm) On weight loss drugs (e.g., Xenical (orilistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine

2013 Clinical Trials

218. Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo

-IV) defined eating disorder Use of, or clinical indication for, one or more of the following medications: lithium, anti-epileptic medication, steroids (oral or inhaled), stimulants, serotonin reuptake inhibitors, mirtazapine, tricyclic antidepressants, thyroid supplementation, sibutramine, metformin, thiazolidinediones, beta-blockers, clonidine, niacin Subjects who have had >10% change in their body weight within the three months prior to enrollment HIV positive subjects Presence of mental

2013 Clinical Trials

219. Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis

/intervention 4)Hepatic cirrhosis with Child-Pugh score of B or C, and/or concomitant HCC 5)Recent(within 6 months) or concomitant use of agents known to cause hepatic steatosis 7)Recent(within 6 months)change in dose/regimen or first treatment with vitamin E, C, betaine, s-adenosylmethionine, ursodeoxycholate, sylimarin, fibrate, statin, pentoxyfilline, angiotensin II inhibitors, orlistat, sibutramine 8)Ongoing or recent therapy (within 6 months) with vitamin D or with medications known to affect vitamin

2013 Clinical Trials

220. Vascular Dysfunction in Human Obesity Hypertension

), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications) within 3 months of screening Any surgery within 30 days of screening Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01983462 Contacts Layout table

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>